1
|
Kanyike AM, Kakuba F, Mayambala P, Nalunkuma R, Nakandi RM, Mulumba Y, Namulema E, Nsingo SP, Ssebuufu R. Prevalence trends of transfusion-transmitted infections at a tertiary private hospital blood bank in Uganda: a retrospective 6-year review (2017-2022). BMC Infect Dis 2025; 25:672. [PMID: 40335905 DOI: 10.1186/s12879-025-10882-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2024] [Accepted: 04/01/2025] [Indexed: 05/09/2025] Open
Abstract
BACKGROUND Blood transfusion is a life-saving medical intervention that can transmit transfusion-transmitted infections (TTIs). In Uganda, prevalent infections in the general population may increase the risk of TTIs. This study determined the trends in seroprevalence of TTIs, including the Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and syphilis among blood donations over a 6-year period at a tertiary hospital blood bank in Uganda. METHODS This was a retrospective cross-sectional study utilizing data from Mengo Hospital Rotary Blood Bank in central Uganda. Data was accessed through the central electronic system of Uganda Blood Transfusion Services for January 2017 to December 2022. Data was analyzed using STATA version 16.0. Descriptive statistics and time trend analysis were performed. A p-value < 0.05 was considered statistically significant. RESULTS We analyzed 24,547 blood donations, the majority of which were male donors (18,525, 75.5%) within the age group of 25-40 years (9737, 39.7%) and of Blood group O (12,509, 51.0%). The overall prevalence of TTIs was 8.7% (2,142) and significantly higher among males (8.9%, p < 0.001) and those over 40 years (10.7%, p < 0.01). Syphilis had the highest prevalence at 3.0%, followed by HBV (2.8%), HCV (1.7%), and HIV (1.3%). Co-infections were observed in 0.6% (136) of the donors, with the most common being HBV and syphilis (33, 0.1%). The prevalence trends of TTIs analysed among new donations decreased from 13.7% in 2017 to 8.9% in 2022 (p = 0.124). Only HCV showed a statistically significant variation, decreasing from 5.2% in 2017 to 1.7% in 2022 (p = 0.009). CONCLUSION There is a decreasing trend of TTIs among blood donors in Central Uganda, although the prevalence of HBV and Syphilis remains high. Additional public health interventions to decrease TTI rates in the general population may increase the safety of blood transfusions.
Collapse
|
2
|
Habibu I, Abubakar BM, Moi IM, Abdulrazaq R. Seroprevalence of HIV, HBV, HCV and Syphilis among blood donors in a Nigerian tertiary medical centre. BMC Infect Dis 2025; 25:638. [PMID: 40307693 PMCID: PMC12044881 DOI: 10.1186/s12879-025-11024-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2024] [Accepted: 04/21/2025] [Indexed: 05/02/2025] Open
Abstract
BACKGROUND Transfusion-transmitted infections (TTIs), such as HIV, HBV, HCV, and Syphilis, present considerable difficulties in maintaining blood quality despite the critical role of blood transfusion in emergency medical care. This study aims to ascertain the prevalence of these infections and the factors that increase their risk among those who donate blood. METHODS A cross-sectional study was conducted at the Federal Medical Center in Azare, involving 400 blood donors. Serological tests were conducted for HBV, HCV, HIV, and syphilis, and sociodemographic data was collected through a structured questionnaire. The univariate and multivariate logistic regression tests were employed to detect associated risk factors, with a significance level set at P < 0.05. RESULT Of the total blood donors, 17.00% (68/400) tested positive for at least one TTIs. The presence of HIV, HBV, HCV, and syphilis was identified in 2.8% (11/400), 8.3% (33/400), 1.8% (7/400), and 4.3% (17/400) of the donors, respectively. Multivariate analysis, after adjustments with various variables, indicates only commercial blood donors [Adjusted Odds Ratio (AOR) (95% CI): 14.63 (1.76-121.27)] and multiple sexual partners [AOR (95% CI): 5.40 (1.28-22.70)] were associated with HIV, while blood transfusion and piercing or tattoo were associated with HBV. Multiple sexual partners and a history of STDs were associated with syphilis infection. CONCLUSION TTIs such as HIV, HBV, HCV, and syphilis were detected among the blood donors, with HBV being the most common. The findings highlight a gender disparity in blood donation, with voluntary donors comprising the majority; nevertheless, commercial donors had the highest prevalence of TTIs. Enhanced donor screening and public awareness are crucial for blood safety. CLINICAL TRIAL NUMBER Not applicable.
Collapse
Affiliation(s)
- Ismail Habibu
- Department of Biological Sciences, Bauchi State University Gadau, PMB 065, Bauchi, Nigeria
| | | | - Ibrahim Musa Moi
- Department of Microbiology, Bauchi State University Gadau, PMB 065, Bauchi, Nigeria
| | - Rabiu Abdulrazaq
- Department of Laboratory Services, Federal Medical Centre, PMB 005, Azare, Bauchi, Nigeria
| |
Collapse
|
3
|
Kassa GM, Weldemariam AG, Abrahim SA, French CE, Wolday D, Dagne E, Mulu A, Adane A, Inglis SK, Radley A, Tasew G, Vickerman P, Yesuf EA, Paltiel O, Hailu M, Amogne W, Dillon JF, Hickman M, Lim AG, Walker JG. Seroprevalence of Hepatitis C in Ethiopia: First National Study Based on the 2016 Ethiopian Demographic and Health Survey. J Viral Hepat 2025; 32:e14037. [PMID: 39569765 PMCID: PMC11883455 DOI: 10.1111/jvh.14037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/05/2024] [Revised: 10/18/2024] [Accepted: 11/04/2024] [Indexed: 11/22/2024]
Abstract
Hepatitis C virus (HCV) is hypothesised to be a public health problem in Ethiopia, and systematic review evidence suggested 1%-3% seroprevalence. We aimed to estimate the seroprevalence of HCV overall and across regions of Ethiopia. We estimated HCV seroprevalence using the 2016 Ethiopian Demographic and Health Survey (EDHS-2016). EDHS-2016 is a nationwide household survey conducted using two-stage cluster sampling methods. We tested all 26,753 samples from participating adult women (15-49 years) and men (15-59 years) using HCV Enzyme Immunoassay. Descriptive analyses were performed based on the Guide to Demographic Health Survey statistics. We applied sample weighting to derive representative estimates. Of the total tested, more than half (54.40%) were aged 15-29 years and 51.59% were women. Overall HCV seroprevalence was 0.18% (95% Confidence Interval: 0.10-0.32). Higher seroprevalences were found in Afar (0.92%) and South Nations Nationality Peoples Region (0.43%); people living with HIV (PLWH) (0.62%); the poorest wealth index (0.35%); people having multiple lifetime sexual partners (0.31%); and widowed/divorced individuals (0.30%). In stratified analyses by sex and residency, we found higher seroprevalences in non-Christian and non-Muslim males (1.98%) and rural population (1.00%), male PLWH (1.67%), rural PLWH (1.45%), widowed/divorced males (0.97%), and in all groups from the Afar region: males (1.30%), females (0.61%), urban (1.07%), and rural (0.86%). HCV seroprevalence among the general population in Ethiopia is much lower than from previous estimates. General population screening is unlikely to be cost-effective, and so screening programs targeted to people at greater risk of HCV will be required.
Collapse
Affiliation(s)
- Getahun Molla Kassa
- Population Health Sciences, Bristol Medical SchoolUniversity of BristolBristolUK
- Department of Epidemiology and Biostatistics, Institute of Public Health, College of Medicine and Health SciencesUniversity of GondarGondarEthiopia
| | - Atsbeha Gebreegziabxier Weldemariam
- Ethiopian Public Health InstituteAddis AbabaEthiopia
- Division of Molecular and Clinical Medicine, School of MedicineUniversity of DundeeDundeeUK
| | | | - Clare E. French
- Population Health Sciences, Bristol Medical SchoolUniversity of BristolBristolUK
- NIHR Health Protection Research Unit in Behavioural Science and Evaluation at University of BristolBristolUK
| | - Dawit Wolday
- Ethiopian Public Health InstituteAddis AbabaEthiopia
- Department of Biochemistry & Biomedical SciencesMcMaster UniversityHamiltonOntarioCanada
| | - Emebet Dagne
- Department of Internal Medicine, Institute of HealthJimma UniversityJimmaEthiopia
| | | | - Aynishet Adane
- Department of Internal Medicine, School of Medicine, College of Medicine and Health SciencesUniversity of GondarGondarEthiopia
| | | | - Andrew Radley
- Division of Public Health and Genomics, School of MedicineUniversity of DundeeDundeeUK
| | - Geremew Tasew
- Ethiopian Public Health InstituteAddis AbabaEthiopia
| | - Peter Vickerman
- Population Health Sciences, Bristol Medical SchoolUniversity of BristolBristolUK
| | - Elias Ali Yesuf
- Department of Health Policy and Management, Institute of HealthJimma UniversityJimmaEthiopia
| | - Ora Paltiel
- Department of Hematology and Braun School of Public HealthHadassah‐Hebrew University Faculty of MedicineJerusalemIsrael
| | - Mesay Hailu
- Ethiopian Public Health InstituteAddis AbabaEthiopia
| | - Wondwossen Amogne
- Department of Internal Medicine, School of Medicine, College of Health SciencesAddis Ababa UniversityAddis AbabaEthiopia
| | - John F. Dillon
- Division of Molecular and Clinical Medicine, School of MedicineUniversity of DundeeDundeeUK
| | - Matthew Hickman
- Population Health Sciences, Bristol Medical SchoolUniversity of BristolBristolUK
| | - Aaron G. Lim
- Population Health Sciences, Bristol Medical SchoolUniversity of BristolBristolUK
| | - Josephine G. Walker
- Population Health Sciences, Bristol Medical SchoolUniversity of BristolBristolUK
| |
Collapse
|
4
|
Cwinyaai N, Opio D, Kajumbula H, Zalwango JF, Akunzirwe R, Okello T, Francis A. Prevalence and Factors Associated with transfusion-transmissible infections among blood donors in Arua regional blood bank, Uganda. BMC Infect Dis 2024; 24:926. [PMID: 39242507 PMCID: PMC11380187 DOI: 10.1186/s12879-024-09838-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2024] [Accepted: 08/29/2024] [Indexed: 09/09/2024] Open
Abstract
BACKGROUND Blood transfusion services play a very key role in modern health care service delivery. About 118.5 million blood donations were collected globally in 2022. However, about 1.6 million units of blood are destroyed annually due to transfusion-transmissible infections (TTIs). There is a very high risk of TTIs through donated blood to recipients if safe transfusion practices are not observed. This study determined the prevalence and factors associated with TTIs among blood donors in Arua regional blood bank, Uganda. METHODS This study was a retrospective cross-sectional design that involved a review of a random sample of 1370 blood donors registered between January 1st, 2018 and December 31st, 2019 at Arua regional blood bank, Uganda. Descriptive statistics were used to describe the characteristics of the blood donors. The binary logistic regression was used to determine the factors associated with TTIs. RESULTS The majority of the blood donors were male (80.1%), and the median donor age was 23 years (IQR = 8 years). The overall prevalence of TTIs was found to be 13.8% (95%CI: 12.0-15.6%), with specific prevalences of 1.9% for HIV, 4.1% for HBV, 6.6% for HCV and 2.8% for treponema pallidum. Male sex (AOR = 2.10, 95%CI: 1.32-3.36, p-value = 0.002) and lapsed donor type compared to new donor type (AOR = 0.34, 95%CI: 0.13-0.87, p-value = 0.025) were found to be associated with TTIs. CONCLUSION The prevalence of TTIs among blood donors of West Nile region, Uganda was found to be significantly high, which implies a high burden of TTIs in the general population. Hence, there is need to implement a more stringent donor screening process to ensure selection of risk-free donors, with extra emphasis on male and new blood donors. Additionally, sensitization of blood donors on risky behaviors and self-deferral will reduce the risk of donating infected blood to the recipients.
Collapse
Affiliation(s)
- Norman Cwinyaai
- Clinical Epidemiology Unit, Makerere University College of Health Sciences, Kampala, Uganda.
| | - Denis Opio
- Clinical Epidemiology Unit, Makerere University College of Health Sciences, Kampala, Uganda
- Epicentre- MSF, Quartier Plateau, Boulevard Mali Bero, Niamey, Niger
| | - Henry Kajumbula
- School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda
| | - Jane F Zalwango
- Clinical Epidemiology Unit, Makerere University College of Health Sciences, Kampala, Uganda
| | - Rebecca Akunzirwe
- Clinical Epidemiology Unit, Makerere University College of Health Sciences, Kampala, Uganda
| | - Tom Okello
- Clinical Epidemiology Unit, Makerere University College of Health Sciences, Kampala, Uganda
| | - Anguzu Francis
- Clinical Epidemiology Unit, Makerere University College of Health Sciences, Kampala, Uganda
| |
Collapse
|
5
|
Duracinsky M, Yaya I, Yombo-Kokule L, Bessonneau P, Thonon F, Rousset-Torrente O, Roudot-Thoraval F, Lert F, Zucman D, Chassany O. Development of a risk prediction score for screening for HBV, HCV and HIV among migrants in France: results from a multicentre observational study (STRADA study). BMJ Open 2024; 14:e075315. [PMID: 38839381 PMCID: PMC11163614 DOI: 10.1136/bmjopen-2023-075315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/04/2023] [Accepted: 12/14/2023] [Indexed: 06/07/2024] Open
Abstract
OBJECTIVES Migrants from high HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) endemicity regions have a great burden of these infections and related diseases in the host countries. This study aimed to assess the predictive capacity of the Test Rapide d'Orientation Diagnostique (TROD) Screen questionnaire for HIV, HBV and HCV infections among migrants arriving in France. DESIGN An observational and multicentre study was conducted among migrants. A self-questionnaire on demographic characteristics, personal medical history and sexual behaviours was completed. SETTING The study was conducted in the centres of the French Office for Immigration and Integration (OFII). PARTICIPANTS Convenience sampling was used to select and recruit adult migrants between January 2017 and March 2020. OUTCOME MEASURES Participants were tested for HIV, HBV and HCV with rapid tests. For each infection, the test performance was assessed using receiver operating characteristics curves, using area under the curve (AUC) as a measure of accuracy. RESULTS Among 21 133 regular migrants seen in OFII centres, 15 343 were included in the study. The participants' mean age was 35.6 years (SD±11.1). The prevalence (95% CI) of HBV, HCV and HIV was 2.0% (1.8% to 2.2%), 0.3% (0.2% to 0.4%) and 0.3% (0.2% to 0.4%), respectively. Based on the sensitivity-specificity curve analysis, the cut-off points (95% CI) chosen for the risk score were: 2.5 (2.5 to 7.5) for HBV infection in men; 6.5 (0.5 to 6.5) for HBV infection in women; 9.5 (9.5 to 12.5) for HCV infection; and 10.5 (10.0 to 18.5) for HIV infection. Test performance was highest for HIV (AUC=82.15% (95% CI 74.54% to 87.99%)), followed by that for HBV in men (AUC=79.22%, (95% CI 76.18% to 82.26%)), for HBV in women (AUC=78.83 (95% CI 74.54% to 82.10%)) and that for HCV (AUC=75.95% (95% CI 68.58% to 83.32%)). CONCLUSION The TROD screen questionnaire showed good overall performance for predicting HIV, HBV and HCV infections among migrants in OFII centres. It could be used to optimise screening for these infections and to propose rapid screening tests to those who are at high risk. TRIAL REGISTRATION NUMBER NCT02959684.
Collapse
Affiliation(s)
- Martin Duracinsky
- Patient-Reported Outcomes Research (PROQOL), Health Economics Clinical Trial Unit (URC-ECO), Hotel-Dieu Hospital, AP- HP, Paris, France
- ECEVE, UMR-S 1123, Paris Cité University, Inserm, Paris, France
- Internal Medicine Unit, Le Kremlin Bicêtre Hospital, Bicêtre, France
| | - Issifou Yaya
- Patient-Reported Outcomes Research (PROQOL), Health Economics Clinical Trial Unit (URC-ECO), Hotel-Dieu Hospital, AP- HP, Paris, France
- ECEVE, UMR-S 1123, Paris Cité University, Inserm, Paris, France
| | - Lisa Yombo-Kokule
- Patient-Reported Outcomes Research (PROQOL), Health Economics Clinical Trial Unit (URC-ECO), Hotel-Dieu Hospital, AP- HP, Paris, France
- ECEVE, UMR-S 1123, Paris Cité University, Inserm, Paris, France
| | - Pascal Bessonneau
- Patient-Reported Outcomes Research (PROQOL), Health Economics Clinical Trial Unit (URC-ECO), Hotel-Dieu Hospital, AP- HP, Paris, France
- ECEVE, UMR-S 1123, Paris Cité University, Inserm, Paris, France
| | - Frédérique Thonon
- Patient-Reported Outcomes Research (PROQOL), Health Economics Clinical Trial Unit (URC-ECO), Hotel-Dieu Hospital, AP- HP, Paris, France
- ECEVE, UMR-S 1123, Paris Cité University, Inserm, Paris, France
| | - Olivia Rousset-Torrente
- Patient-Reported Outcomes Research (PROQOL), Health Economics Clinical Trial Unit (URC-ECO), Hotel-Dieu Hospital, AP- HP, Paris, France
- ECEVE, UMR-S 1123, Paris Cité University, Inserm, Paris, France
| | | | - France Lert
- Paris Fast Track City Initiative (FTCI) program, Paris, France
| | - David Zucman
- Department of Internal Medicine, Foch Hospital, Suresnes, France
| | - Olivier Chassany
- Patient-Reported Outcomes Research (PROQOL), Health Economics Clinical Trial Unit (URC-ECO), Hotel-Dieu Hospital, AP- HP, Paris, France
- ECEVE, UMR-S 1123, Paris Cité University, Inserm, Paris, France
| |
Collapse
|
6
|
Jentsch U, Vermeulen M, van den Berg K, Swanevelder R, Creel D, Jacobs G, Hemingway-Foday JJ, Nyoni C, Murphy EL, Custer B. A case-control study of risk factors for incident hepatitis B virus infection in South African blood donors. Int J Infect Dis 2024; 141:106958. [PMID: 38373648 PMCID: PMC11034725 DOI: 10.1016/j.ijid.2024.02.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2023] [Revised: 01/19/2024] [Accepted: 02/01/2024] [Indexed: 02/21/2024] Open
Abstract
OBJECTIVES Hepatitis B virus (HBV) infection remains a global health problem. Risk factors for HBV infection are usually assessed in prevalent rather than incident infections. To identify demographic and behavioral risks associated with incident HBV among South African blood donors. METHODS A case-control study was performed between November 2014 and January 2018. Cases were blood donors testing positive for HBV DNA with or without hepatitis B surface antigen but negative for antibody to hepatitis B core antigen. Participants completed an audio computer-assisted structured interview on exposures during the previous 6 months. Sex-specific multivariable logistic regression yielded independent associations between risks and HBV infection. RESULTS 56 females and 37 males with incident HBV were compared to 438 female and 439 male controls, respectively. For females, risk factors were accepting money or goods for sex, using agents to prepare one's anus prior to anal sex, penetrating injury, non-Black race, and lower educational status. Men reporting homosexual or bisexual orientation or sex with other men, previous injury, referral for HBV testing, or lack of medical insurance were at increased risk. For both sexes, having more than two male sexual partners increased risk. CONCLUSIONS Sexual behaviors predominated over parenteral exposures as risks for incident HBV in both female and male blood donors.
Collapse
Affiliation(s)
- Ute Jentsch
- The South African National Blood Service, Johannesburg, South Africa.
| | - Marion Vermeulen
- The South African National Blood Service, Johannesburg, South Africa; University of the Free State, Bloemfontein, South Africa
| | - Karin van den Berg
- The South African National Blood Service, Johannesburg, South Africa; University of the Free State, Bloemfontein, South Africa
| | - Ronél Swanevelder
- The South African National Blood Service, Johannesburg, South Africa
| | | | - Genevieve Jacobs
- The South African National Blood Service, Johannesburg, South Africa
| | | | - Cynthia Nyoni
- The South African National Blood Service, Johannesburg, South Africa
| | - Edward L Murphy
- University of California San Francisco, San Francisco, USA; Vitalant Research Institute, San Francisco, USA
| | - Brian Custer
- Vitalant Research Institute, San Francisco, USA; University of California San Francisco, San Francisco, USA
| |
Collapse
|
7
|
Walana W, Vicar EK, Kuugbee ED, Dari I, Bichenlib G, Aneba CN, Hinneh KN, Yabasin IB, Issaka KN, Danso MO, Amoatey TN, Ziem JB. Transfusion transmissible infections among blood donors in Ghana: A 3-year multicentered health facility-based retrospective study. Health Sci Rep 2023; 6:e1681. [PMID: 37927541 PMCID: PMC10620378 DOI: 10.1002/hsr2.1681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2023] [Revised: 10/17/2023] [Accepted: 10/19/2023] [Indexed: 11/07/2023] Open
Abstract
Transfusion transmissible infections (TTIs) remain a major health challenge particularly in developing countries. Here, we present a multicentered hospital-based retrospective study on the prevalence, distribution, and risk factors of TTIs in Ghana. Data on blood donors from four health facilities, namely Nkwanta South Municipal Hospital (Oti region), Weija-Gbawe Municipal Hospital (Greater Accra region), SDA Hospital (Northern region) and Wa Municipal Hospital (Upper West region) were extracted and analyzed. Descriptive statistics and multinomial logistic regression were applied to compare sociodemographic data with TTI status. A total of 6094 blood donors were included in this study, and 2% were females. The overall prevalence of TTIs was 21.0% (1232/5868). Specifically, the prevalence of HBV, HCV, HIV, and Syphilis was 6.6% (385/5868), 4.9% (286/5830), 2.9% (168/5867), and 6.8% (393/5739), respectively. Wa dominated in all the viral agents considered in this study, while the Oti region recorded the highest prevalence in T. pallidum. The odds of HBV infection was 3.1 (p = 0.008) among first-time donors, while that for HCV was 2.8 (p = 0.042). For rural dwellers, donors significantly had T. pallidum (p < 0.001; OR = 2.8), HCV (p < 0.001; OR = 2.9), and HIV (p = 0.028; OR = 1.5) infections. Generally, the recipients of transfused blood were predominantly pregnant mothers, followed by children and accident victims. This study has revealed significant disparities and relatively high prevalence of TTIs in Ghana, specifically HBV, HCV, HIV and T. pallidum infections. The variations suggest the presence of unique health challenges per study area, hence the need for a tailored intervention for each study site.
Collapse
Affiliation(s)
- Williams Walana
- Department of Clinical MicrobiologySchool of Medicine, University for Development StudiesTamaleGhana
| | - Ezekiel K. Vicar
- Department of Clinical MicrobiologySchool of Medicine, University for Development StudiesTamaleGhana
| | - Eugene D. Kuugbee
- Department of Microbiology and ImmunologySchool of Medicine and DentistryNavrongoGhana
| | - Isaac Dari
- Community Health and Preventive MedicineSchool of Medicine, University for Development StudiesTamaleGhana
| | - Grace Bichenlib
- Community Health and Preventive MedicineSchool of Medicine, University for Development StudiesTamaleGhana
| | - Christian N. Aneba
- Community Health and Preventive MedicineSchool of Medicine, University for Development StudiesTamaleGhana
| | - Kwasi N. Hinneh
- Community Health and Preventive MedicineSchool of Medicine, University for Development StudiesTamaleGhana
| | - Iddrisu B. Yabasin
- Department of Anaesthesiology and Intensive CareUniversity for Development StudiesTamaleGhana
| | - Koray N. Issaka
- Department of Laboratory ServiceWa Municipal Hospital, Upper West RegionWaGhana
| | - Michael O. Danso
- Department of Laboratory ServiceWeija‐Gbawe Municipal Hospital, Greater Accra RegionAccraGhana
| | | | - Juventus B. Ziem
- Department of Microbiology and ImmunologySchool of Medicine and DentistryNavrongoGhana
| |
Collapse
|
8
|
Belkacemi M, Merbouh MA. Seroprevalence of Human Immunodeficiency Virus, Hepatitis C Virus, and Hepatitis B Virus Among Blood Donors in Sidi Bel Abbes, West Algeria. Cureus 2023; 15:e47066. [PMID: 38022198 PMCID: PMC10644989 DOI: 10.7759/cureus.47066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/13/2023] [Indexed: 12/01/2023] Open
Abstract
Introduction Blood transfusions can transmit various viruses. Among them, the most common are hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). These viruses can cause fatal and life-threatening diseases. Worldwide, many people are infected with these viruses. Blood safety has made major progress in recent years. Yet, blood-borne viruses continue to be a major concern for patients, physicians, and policymakers. The aim of this study was to assess the prevalence of HIV, HBV, and HCV in blood donors. Methods A cross-sectional study was performed to assess HIV, HBV, and HCV seropositivity in blood donors. This research was carried out at the blood bank of Sidi Bel Abbes University Hospital. This was a retrospective study based on records of blood donors. All data of 10,386 donors were analyzed from January 2015 to December 2015. Biological screening was performed by enzyme-linked immunosorbent assay (ELISA) using antibodies and/or antigens. The combined HCV and HIV antigen and antibody ELISA test was utilized. To confirm the results, the blood bank and the virology laboratory used the same technique in duplicate. Results The overall seroprevalence of blood-borne viral infections (HIV, HBV, and HCV) in blood donors was 0.8%. The prevalence of HIV was found to be 0.1%, while the prevalence of HBV and HCV was 0.4%. Coinfection was rare with only one case of HBV with HIV. There was a significant difference in seroprevalence rates among blood donors compared to the general population. Significant variations were observed between the prevalence of this study and those conducted in West, East, Central, and South African countries but not with those of neighboring North African countries. The study found no association between seropositivity in blood donors and factors like age, gender, donor status, type of donation, or site. Besides, HIV, HBV, or HCV prevalence was not influenced by ABO and Rhesus blood group. Conclusion The study showed that blood donors in Algeria have a lower prevalence of blood-borne viral infections than the general population. The seropositivity rate of viral markers was similar throughout North African countries. This rate remained low compared to other African countries. Residual risk of infection persists. There is a need to increase blood safety for recipients. This report is the first comprehensive overview of blood-borne viruses among Algerian blood donors. There is a need for further nationwide studies to get a whole picture of the situation.
Collapse
Affiliation(s)
- Malika Belkacemi
- Hemobiology and Blood Transfusion, University Hospital Establishment of Oran, Oran, DZA
- Medicine, Oran 1 University, Oran, DZA
| | - Mohammed Amine Merbouh
- Epidemiology and Preventive Diseases, Hassani Abdelkader University Hospital, Sidi Bel Abbes, DZA
- Medicine, Djilali Liabès University, Sidi Bel Abbes, DZA
| |
Collapse
|
9
|
Miyano S, Pathammavong C, Ichimura Y, Sugiyama M, Phounphenghack K, Tengbriacheu C, Khamphaphongphane B, Nouanthong P, Franzel L, Yang TU, Raaijimakers H, Ota T, Funato M, Komada K, Hachiya M. Prevalence of hepatitis B and C virus infections in Lao People's Democratic Republic: The first national population-based cross-sectional survey. PLoS One 2022; 17:e0278933. [PMID: 36584043 PMCID: PMC9803141 DOI: 10.1371/journal.pone.0278933] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2022] [Accepted: 11/23/2022] [Indexed: 12/31/2022] Open
Abstract
Population-based seroprevalence of chronic hepatitis B and C infections has not been examined in Lao People's Democratic Republic (PDR). Therefore, this study aimed to estimate the seroprevalence of these infections in the general population of Lao PDR and perform subgroup analysis. A nationwide seroprevalence survey was conducted in Lao PDR in June 2019 using the multistage cluster sampling method. Dried blood spot samples were collected onto WhatmanTM 903 filter paper by finger prick. A chemiluminescent microparticle immunoassay was used to measure the levels of hepatitis B surface antigen (HBsAg) and hepatitis C antibody (HCV-Ab). Samples in which the HBsAg level was above 0.05 IU/ml and HCV-Ab was above the signal/cutoff ratio of 1.0 were considered positive based on comparisons with the relative light unit value of a calibration sample. A total of 1,927 samples (male: 47.3%, mean age: 23.0 years) were included in the analysis. The prevalence was estimated to be 4.2% (95% confidence interval [CI]: 2.7-6.3) for HBsAg and 1.6% (95% CI: 0.5-5.3) for HCV-Ab. Multivariable analysis revealed that those aged 20-24 years (adjusted odds ratio (AOR): 2.3, 95% CI: 1.1-4.6), those aged 25-29 years (AOR: 2.7, 95% CI: 1.3-5.6), those from the Northern region (AOR: 2.8, 95% CI: 1.2-6.6), and those who were Khmu (AOR: 3.6, 95% CI: 2.0-6.8) or Hmong (AOR: 5.0, 95% CI: 3.3-7.5) were significantly more likely to be positive for HBsAg. Although there were no statistically significant differences in the HCV-Ab prevalence according to each variable, males (2.9%, 95% CI: 0.7-10.7), those aged ≥40 years (6.1%, 95% CI: 2.1-16.8), and those from the Southern region (3.3%, 95% CI: 0.6-15.3) tended to have a higher prevalence. This novel population-based survey found differences in the prevalence of chronic hepatitis B and hepatitis C virus infections in Lao PDR according to sex, age group, region, and ethnicity; however, the results of this study should be confirmed in future studies, and relevant responses tailored for each target also need to be determined to control the transmission of hepatitis B and C infections.
Collapse
Affiliation(s)
- Shinsuke Miyano
- Bureau of International Health Cooperation and WHO Collaborating Center for Health Systems Development, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan
- * E-mail:
| | - Chansay Pathammavong
- National Immunization Program, Mother and Child Health Center, Ministry of Health, Lao People’s Democratic Republic (Lao PDR), Vientiane Capital, Lao PDR
| | - Yasunori Ichimura
- Bureau of International Health Cooperation and WHO Collaborating Center for Health Systems Development, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan
| | - Masaya Sugiyama
- Genome Medical Science Project, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikwa, Chiba, Japan
| | - Kongxay Phounphenghack
- National Immunization Program, Mother and Child Health Center, Ministry of Health, Lao People’s Democratic Republic (Lao PDR), Vientiane Capital, Lao PDR
| | | | | | - Phonethipsavanh Nouanthong
- Institute Pasteur du Laos, National Immunization Technical Advisory Group, Ministry of Health, Vientiane Capital, Lao PDR
| | - Lauren Franzel
- Vaccine-Preventable Diseases and Immunization Team, WHO Lao PDR, Vientiane Capital, Lao PDR
| | - Tae Un Yang
- Vaccine-Preventable Diseases and Immunization Team, WHO Lao PDR, Vientiane Capital, Lao PDR
| | | | - Tomomi Ota
- Bureau of International Health Cooperation and WHO Collaborating Center for Health Systems Development, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan
| | - Masafumi Funato
- Bureau of International Health Cooperation and WHO Collaborating Center for Health Systems Development, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan
| | - Kenichi Komada
- Bureau of International Health Cooperation and WHO Collaborating Center for Health Systems Development, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan
| | - Masahiko Hachiya
- Bureau of International Health Cooperation and WHO Collaborating Center for Health Systems Development, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan
| |
Collapse
|
10
|
Lemma Tirore L, Abose Nadamo S, Tamrat Derilo H, Erkalo D, Sedore T, Tadesse T, Ermias D, Yaekob T. Time to Recovery from Covid-19 and Its Predictors Among Patients Admitted to Treatment Centers of Southern Nations Nationalities and Peoples Region (SNNPR), ETHIOPIA: Multi-Center Retrospective Cohort Study. Infect Drug Resist 2022; 15:3047-3062. [PMID: 35747331 PMCID: PMC9209334 DOI: 10.2147/idr.s365986] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2022] [Accepted: 06/10/2022] [Indexed: 01/08/2023] Open
Abstract
Background The world is currently facing a pandemic of Coronavirus Disease 2019 (Covid-19). It has caused significant morbidity and mortality. So far little is known about recovery time (prolonged hospital stay) from Covid-19 and its determinants in Ethiopia as well as in the study area. Therefore, the aim of this study was to determine time to recovery from Covid-19, and identify predictors of time to recovery among patients admitted to treatment centers of Southern Nations Nationalities and Peoples Region (SNNPR). Methods and Materials A facility-based retrospective cohort study was conducted among Covid-19 patients admitted to care centers of SNNPR from May 30, 2020 to October 15, 2021. A sample of 845 patients was included in the study. Summarization of the data was done using mean (standard deviation) and median (inter quartile range). Kaplan-Meier Survival Curve was used to estimate recovery time from Covid-19 and the independent effects of covariates on recovery time was analyzed using multivariable Cox-proportional hazard model. Results The incidence density of recovery was 8.24 per 100 person-days (95% CI: 7.67, 8.85). The overall median recovery time was 10 days (IQR: 8-16 days). Critical stage of Covid-19 (aHR = 0.19, 95% CI: 0.12, 0.29), severe stage of Covid-19 (aHR = 0.40, 95% CI: 0.29, 0.56), mechanical ventilation (aHR = 0.20, 95% CI: 0.073, 0.56) and treatment center (aHR = 0.68, 95% CI: 0.51, 0.90) were significant predictors of recovery rate among Covid-19 patients. Conclusion The median time to recovery from Covid-19 was relatively short. The incidence density of recovery was 8.24 per 100 person-days. The hazard of recovery was lower for patients at higher levels of Covid-19 severity and for patients in need of mechanical ventilation. Early identification of severity levels of the patients is required at the time of admission. Special attention, critical follow-up and management is warranted for patients at higher levels of Covid-19 severity.
Collapse
Affiliation(s)
| | | | | | - Desta Erkalo
- Department of Public Health, Wachemo University, Hossana, Ethiopia
| | - Tagesse Sedore
- Department of Public Health, Wachemo University, Hossana, Ethiopia
| | - Tegegn Tadesse
- Department of Public Health, Wachemo University, Hossana, Ethiopia
| | - Dejene Ermias
- Department of Public Health, Wachemo University, Hossana, Ethiopia
| | - Temesgen Yaekob
- Department of Statistics, Wachemo University, Hossana, Ethiopia
| |
Collapse
|
11
|
Peliganga LB, Mello VM, de Sousa PSF, Horta MAP, Soares ÁD, Nunes JPDS, Nobrega M, Lewis-Ximenez LL. Transfusion Transmissible Infections in Blood Donors in the Province of Bié, Angola, during a 15-Year Follow-Up, Imply the Need for Pathogen Reduction Technologies. Pathogens 2021; 10:pathogens10121633. [PMID: 34959588 PMCID: PMC8705259 DOI: 10.3390/pathogens10121633] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2021] [Revised: 12/06/2021] [Accepted: 12/09/2021] [Indexed: 12/18/2022] Open
Abstract
Transfusion transmissible infections (TTIs), caused by hepatitis B virus (HBV), human immunode-ficiency virus (HIV), hepatitis C virus (HCV), and syphilis, have a high global impact, especially in sub-Saharan Africa. We evaluated the trend of these infections over time in blood donors in Angola. A retrospective cross-sectional study was conducted among blood donors in Angola from 2005 to 2020. Additionally, frozen samples obtained from blood donors in 2007 were investigated to identify chronic HCV carriers and possible occult HBV infection (OBI). The overall prevalence of HBV, HCV, HIV, and syphilis was 8.5, 3, 2.1, and 4.4%, respectively, among 57,979 blood donors. HBV was predominant among male donors, while the remaining TTIs were predominant among women. Donors >50 years had a significantly high prevalence for all TTIs. Chronic HCV infection was ab-sent in 500 samples tested and OBI was present in 3%. Our results show the continued high prev-alence of TTIs among blood donors in Angola. Most infections showed a significantly low preva-lence in years with campaigns seeking voluntary blood donors, thus, reinforcing the importance of this type of donor to ensure safe blood. Africa, with a high prevalence of diverse pathogens, should consider cost-effective pathogen reduction technologies, once they are commercially accessible, to increase the availability of safe blood.
Collapse
Affiliation(s)
- Luis Baião Peliganga
- Viral Hepatitis Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, Brazil; (L.B.P.); (V.M.M.); (P.S.F.d.S.)
- Disease Control Department, National Directorate of Public Health, Ministry of Health, Luanda, Angola
- Internal Medicine Investigation Department, Faculdade de Medicina da Universidade Agostinho Neto, Luanda, Angola
| | - Vinicius Motta Mello
- Viral Hepatitis Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, Brazil; (L.B.P.); (V.M.M.); (P.S.F.d.S.)
| | - Paulo Sergio Fonseca de Sousa
- Viral Hepatitis Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, Brazil; (L.B.P.); (V.M.M.); (P.S.F.d.S.)
| | | | | | - João Pedro da Silva Nunes
- Laboratory of Experimental Vaccines, Paulista School of Medicine, Federal University of São Paulo, São Paulo 04039-032, Brazil;
| | | | - Lia Laura Lewis-Ximenez
- Viral Hepatitis Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, Brazil; (L.B.P.); (V.M.M.); (P.S.F.d.S.)
- Correspondence: or ; Tel.: +55-(21)-991-921-519
| |
Collapse
|
12
|
Seroprevalence of the Serological Markers of Transfusion-Transmissible Infections among Volunteer Blood Donors of Kosti Obstetrics and Gynecology Hospital. MEDICINES 2021; 8:medicines8110064. [PMID: 34822361 PMCID: PMC8619909 DOI: 10.3390/medicines8110064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/29/2021] [Revised: 09/09/2021] [Accepted: 10/11/2021] [Indexed: 11/16/2022]
Abstract
Background: Transfusion-transmissible infections are well-known global health challenges. The present study is proposed to investigate the seropositivity of anti-HIV1/2, anti-HCV, HBsAg, and anti-T.pallidum among volunteer blood donors of Kosti Obstetrics and Gynecology Hospital. Methods: Our study was conducted in a cross-sectional retrospective manner. The data of donors who attended Kosti Obstetrics and Gynecology Hospital throughout 2016 to 2018 were reviewed and retrieved manually from blood bank records. Results: Out of 8139 donors, 22.52% were seropositive for serological markers of TTIs and 1.67% were seropositive for at least two serological markers of TTIs. The overall seropositivity rate of anti-HIV1/2, HBsAg, anti-HCV, and anti-T.pallidum was 1.77%, 6.07%, 1.14%, and 11.87%, respectively (p < 0.000). Anti-T.pallidum was the most frequently detected (p < 0.05) marker across all study variables. TTIs seroprevalence was significantly (p < 0.05) varied according to the age, residence, occupations, and blood groups. Notably, there was a rising trend in the rate of anti-HIV1/2 and seropositivity for more than one marker with age (p < 0.000). Regionally, rural area residents had a higher rate of anti-HIV1/2 (2.20%), HBsAg (6.31%), anti-HCV (1.42%), anti-T.pallidum (18.38%), and multiple markers seropositivity (2.28%) compared to urban areas. Between occupations, the highest rate of anti-HIV1/2 (p = 0.483), HBsAg (p = 0.003), anti-HCV (p = 0.408), anti-T.pallidum (p < 0.000), and multiple markers seropositivity (p < 0.000) were detected in farmers. Regarding the screening, we also found that the frequency of anti-T.pallidum was significantly (p = 0.003) higher in donors who carry the AB+ve blood group, whereas anti-HCV (1.83%) was more frequent in donors carry O−ve blood group (p = 0.255). As seen, anti-T.pallidum+HBsAg was the most frequently (1.22%) co-occurring markers. In contrast, anti-T.pallidum+anti-HIV1/2+HBsAg was the lowest frequency one (p < 0.000). Conclusions: The study showed an alarming rate of TTIs, which suggests the requirement for comprehensive surveillance and health education programs.
Collapse
|
13
|
Deress T, Million Y, Belachew T, Jemal M, Girma M. Seroprevalence of Hepatitis C Viral Infection in Ethiopia: A Systematic Review and Meta-Analysis. ScientificWorldJournal 2021; 2021:8873389. [PMID: 33897305 PMCID: PMC8052182 DOI: 10.1155/2021/8873389] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2020] [Revised: 02/13/2021] [Accepted: 03/26/2021] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Hepatitis C virus is a highly genetically heterogenous bloodborne pathogen that is responsible for acute and chronic hepatitis. Globally, an estimated 71 million population is chronically infected with this virus from which 399,000 people die every year. Its prevalence is high in Ethiopia and varies from region to region, even among different studies within a region. METHODS Electronic databases, including Science Direct, Medline, HINARI, African Journals Online, TRIP database, African Index Medicus, and Directory of Open Access Journals, searched from 2010 to 2020 and published articles were included. Due to evidence of considerable heterogeneity, the pooled prevalence of anti-HCV was analyzed using the random-effects model. The possible sources of heterogeneity were analyzed through subgroup analysis, sensitivity analysis, and meta-regression. Funnel plots and Egger's test statistics were used to determine the presence of publication bias. RESULTS The analysis of 56 articles showed that the prevalence of anti-HCV in Ethiopia ranged from 0% to 22%. The pooled prevalence estimated was 2% (95% CI 2.0-3.0), and the meta-regression statistics indicated that the diagnostic method (p=0.037), study group (p=0.005), and level of bias (p=0.035) showed statistically significant association with the outcome variable. The sensitivity analysis claims no influence on the overall effect estimate while removing a single study from the analysis at a time. Egger's test statistics (p ≤ 0.001) declare the presence of publication bias that is handled using time and fill analysis. CONCLUSIONS The pooled prevalence of anti-HCV in Ethiopia was high. Predictor variables, including the diagnostic method, study group, and level of bias, showed a statistically significant relationship with the outcome variable. Strengthening the scope of existing prevention and control programs and implementing novel approaches, including screen-and-treat, could significantly help to tackle this critical public health issue. The study provides a current estimate which is valuable for policymakers and other responsible bodies.
Collapse
Affiliation(s)
- Teshiwal Deress
- Unit of Quality Assurance and Laboratory Management, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia
| | - Yihenew Million
- Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia
| | - Teshome Belachew
- Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia
| | - Mohabaw Jemal
- Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia
| | - Mekonnen Girma
- Unit of Quality Assurance and Laboratory Management, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia
| |
Collapse
|
14
|
Wongjarupong N, Oli S, Sanou M, Djigma F, Kiba Koumare A, Yonli AT, Hassan MA, Mara K, Harmsen WS, Therneau T, Barro O, Vodounhessi G, Sawadogo S, Chamcheu JC, Simpore J, Roberts LR, Nagalo BM. Distribution and Incidence of Blood-Borne Infection among Blood Donors from Regional Transfusion Centers in Burkina Faso: A Comprehensive Study. Am J Trop Med Hyg 2021; 104:1577-1581. [PMID: 33617474 PMCID: PMC8045619 DOI: 10.4269/ajtmh.20-0601] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2020] [Accepted: 12/20/2020] [Indexed: 12/15/2022] Open
Abstract
There is a high prevalence of blood-borne infections in West Africa. This study sought to determine the seroprevalence of blood-borne infections, including hepatitis B virus (HBV), hepatitis C virus (HCV), HIV, and syphilis, in blood donors in Burkina Faso. Blood donors were recruited from 2009 to 2013 in four major cities in Burkina Faso of urban area (Ouagadougou) and rural area (Bobo Dioulasso, Fada N’Gourma, and Ouahigouya). Serology tests including hepatitis B surface antigen, anti-HCV, anti-HIV, and rapid plasma reagin test were used for screening and were confirmed with ELISA. Disease prevalence was calculated among first-time donors. Incidence and residual risk were calculated from repeat donors. There were 166,681 donors; 43,084 had ≥ 2 donations. The overall seroprevalence of HBV, HCV, HIV, and syphilis were 13.4%, 6.9%, 2.1%, and 2.4%, respectively. The incidence rates (IRs) of HBV, HCV, HIV, and syphilis infection were 2,433, 3,056, 1,121, and 1,287 per 100,000 person-years. There was lower seroprevalence of HBV and HCV in urban area than in rural area (12.9% versus 14.0%, P < 0.001; and 5.9% versus 8.0%, P < 0.001), and no difference in HIV (2.1% versus 2.1%, P = 0.25). The IRs of new HBV, HCV, HIV, and syphilis were 2.43, 3.06, 1.12, and 1.29 per 100,000 person-years, respectively. The residual risk was one per 268 donations for HBV, one per 181 donations for HCV, and one per 1,480 donations for HIV, respectively. In conclusion, this comprehensive study from four blood donation sites in Burkina Faso showed high HBV and HCV seroprevalence and incidence with high residual risk from blood donation.
Collapse
Affiliation(s)
- Nicha Wongjarupong
- 1Gastroenterology and Hepatology, Mayo Clinic Rochester, Rochester, Minnesota.,2Department of Medicine, University of Minnesota, Minneapolis, Minnesota
| | - Sharad Oli
- 1Gastroenterology and Hepatology, Mayo Clinic Rochester, Rochester, Minnesota
| | - Mahamoudou Sanou
- 3Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA)/LABIOGENE, University of Ouaga I Joseph Ki Zerbo (JKZ), Ouagadougou, Burkina Faso
| | - Florencia Djigma
- 3Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA)/LABIOGENE, University of Ouaga I Joseph Ki Zerbo (JKZ), Ouagadougou, Burkina Faso
| | - Alice Kiba Koumare
- 3Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA)/LABIOGENE, University of Ouaga I Joseph Ki Zerbo (JKZ), Ouagadougou, Burkina Faso
| | - Albert T Yonli
- 3Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA)/LABIOGENE, University of Ouaga I Joseph Ki Zerbo (JKZ), Ouagadougou, Burkina Faso
| | - Mohamed A Hassan
- 1Gastroenterology and Hepatology, Mayo Clinic Rochester, Rochester, Minnesota
| | - Kristin Mara
- 4Division of Biomedical Statistics and Informatics, Mayo Clinic Rochester, Rochester, Minnesota
| | - William S Harmsen
- 4Division of Biomedical Statistics and Informatics, Mayo Clinic Rochester, Rochester, Minnesota
| | - Terry Therneau
- 4Division of Biomedical Statistics and Informatics, Mayo Clinic Rochester, Rochester, Minnesota
| | - Oumar Barro
- 5Division of Hematology and Medical Oncology, Mayo Clinic Arizona, Scottsdale, Arizona
| | - Ghislaine Vodounhessi
- 6Centre National de Transfusion sanguine du Burkina Faso (National Center for Blood Transfusion in Burkina Faso), Ouagadougou, Burkina Faso
| | - Salam Sawadogo
- 6Centre National de Transfusion sanguine du Burkina Faso (National Center for Blood Transfusion in Burkina Faso), Ouagadougou, Burkina Faso
| | - Jean Christopher Chamcheu
- 7School of BPTS, Louisiana College of Pharmacy, University of Louisiana at Monroe, Monroe, Louisiana
| | - Jacques Simpore
- 3Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA)/LABIOGENE, University of Ouaga I Joseph Ki Zerbo (JKZ), Ouagadougou, Burkina Faso
| | - Lewis R Roberts
- 1Gastroenterology and Hepatology, Mayo Clinic Rochester, Rochester, Minnesota
| | - Bolni M Nagalo
- 3Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA)/LABIOGENE, University of Ouaga I Joseph Ki Zerbo (JKZ), Ouagadougou, Burkina Faso.,5Division of Hematology and Medical Oncology, Mayo Clinic Arizona, Scottsdale, Arizona
| |
Collapse
|